Ask AI about FirstString Research
Post your question publicly — other visitors, and whoever manages this page, can answer. It will be visible on this page.
Want to hear about this company again? Follow it and we’ll email you when a new review appears.
AI-generated from reviews on this page. Verify anything important with the company directly.
0 Reviews
Español
No reviews
Questions & Answers
No questions yet — be the first to ask.
Sign in to post
Your text is saved — you'll come right back to post.
Don't have an account? Create one
News & Press
No news yet. This is where the business shares its own updates and press.
Photos
No photos yet. Photos shared by reviewers will show up here.
About FirstString Research
FirstString Research, Inc., a clinical stage biotech company, is leading the translation of cell-cell communication and cell-cell contact/adhesion science into a pipeline of drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The Company has an exclusive worldwide license from the Medical University of South Carolina (MUSC) for the connexin-technology platform and intellectual properties of a portfolio of peptides capable of modulating junctional proteins that are critical for inter-cellular communication. A Phase I human clinical trial demonstrated safety and efficacy of a lead peptide generated from the technology platform. The Company is now advancing GranexinTM Gel, a topical formulation of the lead peptide, through three Phase II human clinical trials for scar reduction and treatment of chronic wounds.
- Website
- firststringresearch.com
- Phone
- 8433883276
- [email protected]
- Address
- 300 W Coleman Blvd Ste 203
